3.00
price down icon3.54%   -0.11
after-market アフターアワーズ: 3.00
loading
前日終値:
$3.11
開ける:
$3.1
24時間の取引高:
176.20K
Relative Volume:
0.47
時価総額:
$130.81M
収益:
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-7.41%
1か月 パフォーマンス:
-22.28%
6か月 パフォーマンス:
-57.02%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
Value
$3.00
$3.11
1週間の範囲:
Value
$3.00
$3.40
52週間の値動き範囲:
Value
$3.00
$30.60

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Name
名前
Kyverna Therapeutics Inc
Name
セクター
Healthcare (1183)
Name
電話
(510) 626-8331
Name
住所
5980 HORTON STREET, EMERYVILLE
Name
職員
119
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
KYTX's Discussions on Twitter

KYTX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KYTX
Kyverna Therapeutics Inc
3.00 130.81M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.32 122.13B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
710.00 78.30B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
646.64 39.73B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.19 35.50B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.61 28.47B 3.30B -501.07M 1.03B -2.1146

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-10 開始されました UBS Buy
2024-10-09 開始されました Rodman & Renshaw Buy
2024-07-03 開始されました H.C. Wainwright Neutral
2024-03-04 開始されました JP Morgan Overweight
2024-03-04 開始されました Leerink Partners Outperform
2024-03-04 開始されました Morgan Stanley Overweight
2024-03-04 開始されました Wells Fargo Overweight
すべてを表示

Kyverna Therapeutics Inc (KYTX) 最新ニュース

pulisher
11:42 AM

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PR Newswire

11:42 AM
pulisher
11:05 AM

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - PR Newswire

11:05 AM
pulisher
05:45 AM

Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire

05:45 AM
pulisher
Feb 06, 2025

The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire

Feb 06, 2025
pulisher
Feb 06, 2025

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX - GlobeNewswire Inc.

Feb 06, 2025
pulisher
Feb 06, 2025

KYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors - The Bakersfield Californian

Feb 06, 2025
pulisher
Feb 05, 2025

Deadline Soon: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire

Feb 05, 2025
pulisher
Feb 04, 2025

Kyverna Therapeutics, Inc. Investors: Please contact the - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesKYTX - PR Newswire

Feb 04, 2025
pulisher
Feb 04, 2025

Class Action Filed Against Kyverna Therapeutics, Inc. - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - Morningstar

Feb 04, 2025
pulisher
Feb 04, 2025

KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Feb 04, 2025
pulisher
Feb 04, 2025

Final Deadline for the Kyverna Therapeutics, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsKYTX - PR Newswire

Feb 04, 2025
pulisher
Feb 04, 2025

KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) DEADLINE ALERT: - GlobeNewswire

Feb 04, 2025
pulisher
Feb 03, 2025

Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) - openPR

Feb 03, 2025
pulisher
Feb 03, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

KYVERNA THERAPEUTICS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc.KYTX - Business Wire

Feb 03, 2025
pulisher
Feb 03, 2025

KYTX FINAL DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

DEADLINE ALERT for BOOM, KYTX, MQ, and SUI: The Law Offices - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

2025-02-03 | KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Kyverna Therapeutics, Inc. to Contact the Firm Today! | NDAQ:KYTX | Press Release - Stockhouse Publishing

Feb 03, 2025
pulisher
Feb 03, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 13.9% in January - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

The Gross Law Firm Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineKYTX - PR Newswire

Feb 03, 2025
pulisher
Feb 03, 2025

Shareholders that lost money on Kyverna Therapeutics, - GlobeNewswire

Feb 03, 2025
pulisher
Feb 02, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - GlobeNewswire

Feb 02, 2025
pulisher
Feb 02, 2025

2025-02-02 | KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:KYTX | Press Release - Stockhouse Publishing

Feb 02, 2025
pulisher
Jan 31, 2025

KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ky - PR Newswire

Jan 31, 2025
pulisher
Jan 31, 2025

KYTX DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, - GlobeNewswire

Jan 31, 2025
pulisher
Jan 31, 2025

KYTX Shareholder Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire

Jan 31, 2025
pulisher
Jan 30, 2025

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - PR Newswire

Jan 30, 2025
pulisher
Jan 30, 2025

Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Deadline Alert: Kyverna Therapeutics, Inc. (KYTX) Investors - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Deadline Alert: Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Urged To Contact Glancy Prongay & - EIN News

Jan 30, 2025
pulisher
Jan 30, 2025

Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before February 7, 2025 to Discuss Your RightsKYTX - PR Newswire

Jan 30, 2025
pulisher
Jan 30, 2025

KYVERNA THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire

Jan 30, 2025
pulisher
Jan 29, 2025

Kyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your ... - The Bakersfield Californian

Jan 29, 2025
pulisher
Jan 28, 2025

KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - GlobeNewswire Inc.

Jan 28, 2025
pulisher
Jan 28, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure ... - The Hastings Tribune

Jan 28, 2025
pulisher
Jan 28, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kyverna - GlobeNewswire

Jan 28, 2025
pulisher
Jan 28, 2025

Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - The Eastern Progress Online

Jan 28, 2025
pulisher
Jan 28, 2025

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - Victoria Advocate

Jan 28, 2025
pulisher
Jan 28, 2025

Kyverna Therapeutics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit - Morningstar

Jan 28, 2025
pulisher
Jan 28, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadli - GuruFocus.com

Jan 28, 2025
pulisher
Jan 28, 2025

Kyverna Therapeutics Class Action: How to File a Claim Against the Firm - Lawyer Monthly Magazine

Jan 28, 2025
pulisher
Jan 28, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - PR Newswire

Jan 28, 2025
pulisher
Jan 27, 2025

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - The Malaysian Reserve

Jan 27, 2025
pulisher
Jan 27, 2025

Kessler Topaz Meltzer & Check, LLP Announces KYTX DEADLINE REMINDER: Important February 7, 2025 Deadline Reminder in Kyverna Therapeutics, Inc. Securities Class Action Lawsuit - Business Wire

Jan 27, 2025

Kyverna Therapeutics Inc (KYTX) 財務データ

Kyverna Therapeutics Inc (KYTX) の財務データはありません。詳細については、他の銘柄を確認してください。

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Kyverna Therapeutics Inc (KYTX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Jones Ryan Alexander
Chief Financial Officer
May 28 '24
Option Exercise
0.73
18,016
13,152
43,950
Vida Ventures, LLC
10% Owner
Feb 12 '24
Buy
22.00
253,136
5,568,992
252,553
Bain Capital Life Sciences Inv
10% Owner
Feb 12 '24
Buy
22.00
450,000
9,900,000
3,163,868
GILEAD SCIENCES, INC.
10% Owner
Feb 12 '24
Buy
22.00
910,000
20,020,000
4,126,119
Northpond Ventures III GP, LLC
Former 10% Owner
Feb 12 '24
Buy
22.00
450,000
9,900,000
450,000
$74.13
price down icon 1.09%
$20.11
price down icon 2.71%
$347.71
price down icon 1.71%
$4.69
price down icon 6.94%
biotechnology ONC
$223.50
price down icon 2.35%
$117.61
price down icon 1.94%
大文字化:     |  ボリューム (24 時間):